Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study

Abstract

BackgroundThe short-term quality of life (QoL) in cervical dystonia (CD) after treating with abobotulinum toxin A (Abo-BTX A) and neubotulinum toxin A (Neu-BTX A) have been studied in Thai CD patients. However; the long-term study has not been published.ObjectiveThe aim of the present study was to determine long-term improvement of the health-related quality of life (HRQoL) after eight injections of Abo-BTX A over 2 years in CD patients.Patients and methodsA 2-year prospective study on the QoL of CD patients, as measured by HRQoL, before and after receiving eight injections of Abo-BTX A at 3-month intervals over a 2-year treatment period was performed. The disease-specific HRQoL was assessed before and after the treatment by using the Cervical Dystonia Impact Profile-58 (CDIP-58) questionnaire. The general HRQoL was assessed by using the Medical Outcomes 36-Item Short Form Health Survey (SF-36), while depressive disorder screening was assessed by using the Center of Epidemiologic Studies-Depression (CES-D) questionnaire. The SF-36 and CES-D questionnaire were administered before treatment and every 3 months before the next injection for a 2-year period.ResultsA total of 20 CD patients were enrolled from January 2013 to December 2015. CDIP-58 showed a significant improvement after long-term injections of Abo-BTX A in all domains (P < 0.001). However, only vitality domain of SF-36, which assessed general HRQoL, showed a significant improvement after long-term injections (P = 0.037). There was no prevalence of depressive disorder in all patients (CES-D score <20) in this study.ConclusionThe Abo-BTX A injections at 3-month intervals over a 2-year period improved the CDIP-58 scores, which assess disease-specific HRQoL, as well as an increased vitality domain of general HRQoL. No patient suffered from depression in this study.

Clinical evaluation of non-motor symptoms in jaw closing dystonia

“…The present patients showed reduced QOL, based on their OHIP-49 and SF-36 scores. Zurowsky et al [27] as well as others have confirmed that psychiatric illnesses have a major impact on QOL of patients with dystonia [34][35][36]. In our study, the dystonia patients consistently demonstrated lower QOL as compared to the healthy controls.…”

Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study

“…However, this study used a large cohort, followed prospectively, and used a longer period of follow-up than that the majority of studies reported. This study was performed in Thailand in the Thai language, but all the PROs used have been previously validated in Thai [28][29][30][31]. Finally, this was an observational study using usual care rather than an intervention; the comparability of generic vs. SLE-specific HRQoL instruments needs to be confirmed in the setting of an interventional trial with an effective agent.…”

“…SLEQOL was developed in Singapore and incorporates questions suitable for oriental cultures [7]. Both SLE-QOL and SF36 surveys have been translated into Thai, validated [28,29], and used in many clinical studies in Thailand [30,31].…”

A Tartaruguinha Que Perdeu O Casco E a Doação De Órgãos: Uma Experiência Inovadora

“…No entanto, a literatura ainda carece de consenso sobre os métodos utilizados para avaliar e monitorar continuamente esses pacientes, devido aos diferentes resultados obtidos de acordo com os instrumentos utilizados. (KONGSAENGDAO & MANEETON, 2018).…”